vs
ANI PHARMACEUTICALS INC（ANIP）とRAYONIER ADVANCED MATERIALS INC.（RYAM）の財務データ比較。上の社名をクリックして会社を切り替えられます
RAYONIER ADVANCED MATERIALS INC.の直近四半期売上が大きい（$417.5M vs $247.1M、ANI PHARMACEUTICALS INCの約1.7倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs -5.0%、差は16.2%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -1.2%）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 3.8%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
RYAM（旧レイヨニア・アドバンスト・マテリアルズ）はセルロース技術で世界的に知られるアメリカ企業です。高純度特殊セルロースを主力事業とし、生産する天然高分子はフィルター製造、食品、医薬品、各種工業分野に幅広く活用されているほか、製紙・包装産業向けの製品も手がけています。
ANIP vs RYAM — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $417.5M |
| 純利益 | $27.5M | $-21.1M |
| 粗利率 | — | 8.9% |
| 営業利益率 | 14.1% | 2.6% |
| 純利益率 | 11.1% | -5.0% |
| 売上前年比 | 29.6% | -1.2% |
| 純利益前年比 | 367.5% | -31.9% |
| EPS（希薄化後） | $1.14 | $-0.33 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $417.5M | ||
| Q3 25 | $227.8M | $352.8M | ||
| Q2 25 | $211.4M | $340.0M | ||
| Q1 25 | $197.1M | $356.0M | ||
| Q4 24 | $190.6M | $422.5M | ||
| Q3 24 | $148.3M | $401.1M | ||
| Q2 24 | $138.0M | $419.0M | ||
| Q1 24 | $137.4M | $387.7M |
| Q4 25 | $27.5M | $-21.1M | ||
| Q3 25 | $26.6M | $-4.5M | ||
| Q2 25 | $8.5M | $-363.2M | ||
| Q1 25 | $15.7M | $-32.0M | ||
| Q4 24 | $-10.3M | $-16.0M | ||
| Q3 24 | $-24.2M | $-32.6M | ||
| Q2 24 | $-2.3M | $11.4M | ||
| Q1 24 | $18.2M | $-1.6M |
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | — | 7.0% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 8.7% | ||
| Q3 24 | — | 10.9% | ||
| Q2 24 | — | 11.5% | ||
| Q1 24 | — | 9.5% |
| Q4 25 | 14.1% | 2.6% | ||
| Q3 25 | 15.9% | 2.8% | ||
| Q2 25 | 6.6% | -0.4% | ||
| Q1 25 | 13.3% | -4.2% | ||
| Q4 24 | -2.3% | 2.6% | ||
| Q3 24 | -13.8% | -4.2% | ||
| Q2 24 | 3.7% | 6.7% | ||
| Q1 24 | 14.8% | 4.4% |
| Q4 25 | 11.1% | -5.0% | ||
| Q3 25 | 11.7% | -1.3% | ||
| Q2 25 | 4.0% | -106.8% | ||
| Q1 25 | 8.0% | -9.0% | ||
| Q4 24 | -5.4% | -3.8% | ||
| Q3 24 | -16.3% | -8.1% | ||
| Q2 24 | -1.7% | 2.7% | ||
| Q1 24 | 13.2% | -0.4% |
| Q4 25 | $1.14 | $-0.33 | ||
| Q3 25 | $1.13 | $-0.07 | ||
| Q2 25 | $0.36 | $-5.44 | ||
| Q1 25 | $0.69 | $-0.49 | ||
| Q4 24 | $-0.45 | $-0.25 | ||
| Q3 24 | $-1.27 | $-0.49 | ||
| Q2 24 | $-0.14 | $0.17 | ||
| Q1 24 | $0.82 | $-0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $75.4M |
| 総負債低いほど良い | — | $758.1M |
| 株主資本純資産 | $540.7M | $316.6M |
| 総資産 | $1.4B | $1.8B |
| 負債/資本比率低いほどレバレッジが低い | — | 2.39× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $75.4M | ||
| Q3 25 | $262.6M | $77.0M | ||
| Q2 25 | $217.8M | $70.7M | ||
| Q1 25 | $149.8M | $129.9M | ||
| Q4 24 | $144.9M | $125.2M | ||
| Q3 24 | $145.0M | $136.1M | ||
| Q2 24 | $240.1M | $114.1M | ||
| Q1 24 | $228.6M | $54.6M |
| Q4 25 | — | $758.1M | ||
| Q3 25 | — | $763.5M | ||
| Q2 25 | — | $720.4M | ||
| Q1 25 | — | $707.0M | ||
| Q4 24 | — | $706.4M | ||
| Q3 24 | — | $747.7M | ||
| Q2 24 | — | $752.8M | ||
| Q1 24 | — | $755.6M |
| Q4 25 | $540.7M | $316.6M | ||
| Q3 25 | $505.8M | $338.2M | ||
| Q2 25 | $436.8M | $342.3M | ||
| Q1 25 | $418.6M | $688.1M | ||
| Q4 24 | $403.7M | $713.9M | ||
| Q3 24 | $405.9M | $732.7M | ||
| Q2 24 | $455.8M | $755.1M | ||
| Q1 24 | $452.0M | $741.8M |
| Q4 25 | $1.4B | $1.8B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.3B | $1.8B | ||
| Q1 25 | $1.3B | $2.1B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.2B | ||
| Q2 24 | $920.8M | $2.2B | ||
| Q1 24 | $914.5M | $2.1B |
| Q4 25 | — | 2.39× | ||
| Q3 25 | — | 2.26× | ||
| Q2 25 | — | 2.10× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 1.02× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | — | 1.02× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $32.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | — |
| FCFマージンFCF / 売上 | 11.8% | — |
| 設備投資強度設備投資 / 売上 | 0.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.10× | — |
| 直近12ヶ月FCF直近4四半期 | $171.4M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $32.3M | ||
| Q3 25 | $44.1M | $-17.8M | ||
| Q2 25 | $75.8M | $-30.2M | ||
| Q1 25 | $35.0M | $39.6M | ||
| Q4 24 | $15.9M | $54.9M | ||
| Q3 24 | $12.5M | $49.8M | ||
| Q2 24 | $17.4M | $87.6M | ||
| Q1 24 | $18.3M | $11.3M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 7.69× | ||
| Q1 24 | 1.00× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RYAM
| Cellulose Specialties | $249.6M | 60% |
| Other | $86.2M | 21% |
| Paperboard | $44.2M | 11% |
| High Yield Pulp | $28.3M | 7% |
| Biomaterials | $9.2M | 2% |
